Loading Content...

Heart Failure precision medicine

THE HUGE BURDEN OF HEART FAILURE DISEASE

After discharge from a Heart Failure hospitalization, patients are at an unacceptably high risk of recurrent hospitalizations or death.

One major origin of post discharge events is the residual patient congestion that is not optimally alleviated at discharge.1 (In fact, many patients leave hospital before their diuretic therapy is optimized)

Another important fact is that patients are discharged before lifesaving renin angiotensin antagonists and mineralocorticoid receptor antagonists could be optimized to reach the highest tolerable doses.2

A wide clinical unmet need

CLINICAL BACKGROUND

GUIDELINES RECOMMEND (grade 1, level of evidence A) OPTIMIZING PHARMACOTHERAPY TO IMPROVE OUTCOMES FOR PATIENTS WITH HEART FAILURE

Optimizing medications belonging to the RAAS inhibitor class (ACE-Is, ARBs and MRAs) have been proven to improve survival and reduce hospitalizations in patients with heart failure.2 In addition, optimizing diuretics reduces volume overload, eases the signs and symptoms of pulmonary congestion and keeps patients out of hospital.2

 

THEN WHY ARE THESE LIFE-SAVING MEDICATION OFTEN UNDER-UTILIZED AND UNDER-DOSED ?

The concerns for raising serum potassium levels, worsening renal function, or inadequate decongestion limit the way these medicines are utilized and dosed.3

Complicating the management of patients with heart failure is the fact that physicians do not have simple, patient-friendly tools to easily keep track of these issues with their patients at home.

We know that optimizing care through disease management programs improves outcomes in patients with heart failure. Up until recently, the focus has been on monitoring pulmonary congestion so that physicians can optimize diuretic doses and reduce admissions.4

But this is only part of the solution.

We also need to be monitoring serum potassium and renal function so that physicians can optimize not just the dose of a diuretic, but also optimize doses of ACE-I, ARB or MRA.

With such a complete view of the status of their HF patient overtime, physicians would feel safe and confident so as to optimize medication precisely to each patient status.

 

What if we could…

If there was a way to reliably, simply and cost-effectively monitor serum potassium, renal function and the degree of congestion in our heart failure patients at home, could we then optimize the use of these life-saving medicines?

With a more comprehensive approach like this, we may be able to reduce not just hospital readmissions, but we may also be able to improve the quality of life and survival of HF patients.

 

References

  1. Coiro S et al: Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail 2015;17:1172–1181.

  2. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure; European Heart Journal (2016) 37, 2129–2200

  3. Epstein M et al: Evaluation of the gap between guidelines and the utilization of RAAS Inhibitors; Am J of Managed Care, 2015, 21, S212-S220

  4. Abraham W et al: Wireless pulmonary artery hemodynamic monitoring in chronic heart failure: a randomized controlled trial; Lancet 2011; 377: 658–66

What we do

CARDIORENAL SOLUTION

CARDIORENAL: GIVING THE PHYSICIAN THE SAFETY NET HE NEEDS TO OPTIMIZE PHARMACOTHERAPY

CardioRenal is developing a simple, non-invasive medical device that will measure serum potassium, renal function and estimated plasma volume (as a surrogate for congestion) at the patient’s home and will provide the information to the patient’s physician in real time….

This medical device is being developed and therefore does not bear the CE-Mark.
This medical device is currently not commerciallys available

Behind the scene

Meet the team

MANAGEMENT TEAM

Maurice Berenger

CEO

Guilhem Henrion

CTO

Charlene Boumard

Regulatory affairs director

Julie Papillon

Operation director

BOARD

Eric LeRoyer

Chairman

Faiez Zannad

Founder

Patrick Rossignol

Founder

Maurice Berenger

CEO

People we works with

OUR PARTNERS

servier
leti cea tech
santeos
sdi
grand est
bpi france
bnp paribas
inserm

Join CardioRenal

Join the team

We are recruting to expand the team competences – Send your application to recruitment@cardio-renal.com

We currently welcome applications for the following positions:

Lets talk and meet

Contact Us

Come visit us

3 sites


11 RUE DE TÉHÉRAN
75015 PARIS


8 AVENUE DANTE
67000 STRASBOURG
17 AVENUE DES MARTYRS
38054 GRENOBLE